Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 13/20 | 0.72 |
| ▸ | S1PR1 | P21453 | 10/20 | 0.72 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | GRK5 | P34947 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30500506 | 1.00 | S1PR5 (0.72) | S1PR5S1PR1FUCA1ALDH1A1S1PR3 | |
| SCHEMBL51920 | 0.90 | S1PR5 (0.81) | S1PR5S1PR1FUCA1S1PR3S1PR4 | |
| SCHEMBL565212 | 0.87 | S1PR5 (0.87) | S1PR5S1PR1FUCA1S1PR3S1PR4 | |
| SCHEMBL5785691 | 0.85 | FUCA1 (0.67) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL12719208 | 0.85 | FUCA1 (0.67) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL1873859 | 0.85 | FUCA1 (0.67) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL1439237 | 0.84 | S1PR5 (0.52) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL29067901 | 0.84 | S1PR5 (0.52) | S1PR5S1PR1FUCA1ALDH1A1 | |
| SCHEMBL3027737 | 0.84 | S1PR5 (1.00) | S1PR5S1PR1S1PR3S1PR4GRK5 | |
| SCHEMBL1439660 | 0.83 | S1PR5 (0.70) | S1PR5S1PR1FUCA1S1PR3S1PR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012101064-A1 | N-ACYL PYRIMIDINE BIARYL COMPOUNDS AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| WO-2012101063-A1 | N-ACYL PYRIDINE BIARYL COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2012-08-02 | — | — | WO | disclosed |
| EP-2473502-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473499-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| EP-2473505-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | Novartis AG (CH) | 2012-07-11 | — | — | EP | disclosed |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | PFISTER KEITH B (US) | 2012-06-21 | — | — | US | disclosed |
| CN-102498107-A | Heteroaryl compounds as kinase inhibitors | NOVARTIS AG | 2012-06-13 | — | — | CN | disclosed |
| CN-102482265-A | Pyrazinylpyridines useful for the treatment of proliferative diseases | NOVARTIS AG | 2012-05-30 | — | — | CN | disclosed |
| CN-102471310-A | Bipyridines useful for the treatment of proliferative diseases | NOVARTIS AG | 2012-05-23 | — | — | CN | disclosed |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | NOVARTIS AG (CH) | 2011-06-02 | — | — | US | disclosed |
| WO-2011026911-A1 | BIPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026917-A1 | HETEROARYL COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
| WO-2011026904-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS AG (CH) | 2011-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157433-A1 | Heteroaryl Compounds as Kinase Inhibitors | CDK2, CDK1, CDK6 | S1PR5 2753/4885S1PR1 2605/4885FUCA1 2213/4885 |
| US-20110130380-A1 | Heteroaryl Kinase Inhibitors | CDK2, CDK1, CDKL1 | S1PR5 3175/4885S1PR1 3068/4885FUCA1 1992/4885 |
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | S1PR5 1610/4885S1PR1 1575/4885FUCA1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.